Peking University Pharmaceuticals announced that Dongxinan Synthetic Pharmaceutical Group Co., Ltd., which holds 21.22% of the shares, will be enforced by the Jinan Intermediate Court due to a financing and securities transaction dispute. This portion of the shares comes from the initial public offering and was held prior to listing. It is planned to reduce holdings through centralized bidding or bulk transactions from August 5 to November 2, 2026. The reduced holdings price will be determined according to the secondary market price. At present, the company's production and operation are normal, and this matter has not had a significant adverse impact.

Peking University Pharmaceuticals announced that Dongxinan Synthetic Pharmaceutical Group Co., Ltd., which holds 21.22% of the shares, will be enforced by the Jinan Intermediate Court due to a financing and securities transaction dispute. This portion of the shares comes from the initial public offering and was held prior to listing. It is planned to reduce holdings through centralized bidding or bulk transactions from August 5 to November 2, 2026. The reduced holdings price will be determined according to the secondary market price. At present, the company's production and operation are normal, and this matter has not had a significant adverse impact.